Takeda Takes Chance On ImmunoGen ADC Tech
This article was originally published in PharmAsia News
Executive Summary
ImmunoGen has seen a partial recovery of its share price on news that Takeda has licensed exclusive rights to its antibody-drug conjugated (ADC) technology to develop anticancer therapeutics to two undisclosed targets. In pre-market trading ImmunoGen's shares rose 17% to $8.71 on the news.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.